CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP
Juno Therapeutics and its partner Sloan Kettering Memorial Cancer Center lose out after the Federal Circuit invalidates a key patent under written description rules
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.